StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
23
Publishing Date
2022 - 12 - 30
1
2022 - 11 - 08
1
2022 - 10 - 20
1
2022 - 10 - 12
1
2022 - 08 - 04
1
2022 - 04 - 22
1
2022 - 04 - 20
1
2022 - 02 - 28
1
2022 - 02 - 10
1
2021 - 12 - 22
1
2021 - 12 - 21
1
2021 - 09 - 24
1
2021 - 09 - 08
1
2021 - 08 - 30
1
2021 - 06 - 30
1
2021 - 06 - 14
1
2021 - 05 - 05
1
2021 - 05 - 03
1
2021 - 04 - 23
1
2021 - 02 - 26
1
2021 - 02 - 22
1
2021 - 01 - 28
1
2020 - 12 - 28
1
Sector
Health technology
23
Tags
Alliances
1
Biocapital
1
Children
1
Clinical-trials-phase-ii
3
Clinical-trials-phase-iii
4
Covid
14
Covid-19
14
Disease
3
Enroll
1
Event-19
2
Expansion
1
Global
1
Infection
1
Infections
1
Infectious disease
1
Influenza
3
Lancet
2
License
1
Malaria
1
N/a
11
Phase 1
2
Phase 2
5
Phase 2b
3
Phase 3
13
Positive
1
Positive results
1
Prototype
2
Research
3
Results
5
Six
1
Trial
20
Trial results
2
Vaccine
22
Entities
Johnson & johnson
1
Novavax, inc.
23
Takeda pharmaceutical company limited
1
Symbols
ABB
72
ABBV
61
ABLZF
31
ALDX
38
ALNY
38
ALPMF
26
ALPMY
26
AMGN
25
ARQT
29
ARVL
26
ATHE
26
ATNM
28
AVXL
24
AZN
64
BGNE
35
BIVI
28
BMY
73
BTAI
26
CLNN
25
CLSD
24
CNHI
69
CYBN
26
CYTK
29
DVAX
28
ENLV
25
EXEL
28
FBIO
41
FDMT
24
FNCTF
90
GIC
38
GILD
48
GTES
25
HON
53
HZNP
46
ICLR
43
IMAB
34
IMMP
34
IMMX
26
INCY
49
JNJ
203
LLY
161
MBRX
34
MDT
25
MRK
71
NVO
41
NVS
34
NVSEF
24
OCGN
26
PDSB
24
PFE
61
PSTV
35
REGN
44
RGNX
29
SNY
310
SNYNF
245
SRNE
38
STAG
32
TAK
56
TGTX
27
TMO
48
Exchanges
Nasdaq
23
Nyse
2
Crawled Date
2022 - 12 - 30
1
2022 - 11 - 08
1
2022 - 10 - 20
1
2022 - 10 - 12
1
2022 - 08 - 04
1
2022 - 04 - 22
1
2022 - 04 - 20
1
2022 - 02 - 28
1
2022 - 02 - 11
1
2021 - 12 - 22
1
2021 - 12 - 21
1
2021 - 09 - 24
1
2021 - 09 - 08
1
2021 - 08 - 30
1
2021 - 06 - 30
1
2021 - 06 - 14
1
2021 - 05 - 06
1
2021 - 05 - 03
1
2021 - 04 - 23
1
2021 - 02 - 26
1
2021 - 02 - 22
1
2021 - 01 - 28
1
2020 - 12 - 28
1
Crawled Time
00:00
1
01:00
2
10:00
2
12:00
1
12:03
1
12:57
1
13:00
2
13:20
2
14:00
1
14:20
1
15:00
1
17:00
1
19:00
1
21:00
1
22:00
1
22:01
1
23:00
3
Source
www.biospace.com
12
www.globenewswire.com
3
www.prnewswire.com
8
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
trial
symbols :
Nvax
save search
Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates
Published:
2022-12-30
(Crawled : 13:20)
- prnewswire.com
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-58.95%
|
O:
-1.34%
H:
7.4%
C:
7.19%
covid-19
vaccine
trial
influenza
phase 2
Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster
Published:
2022-11-08
(Crawled : 14:20)
- biospace.com/
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-79.46%
|
O:
-3.96%
H:
8.79%
C:
5.31%
covid-19
vaccine
prototype
trial
Novavax Showcases Data from Expanding Vaccine Portfolio at IDWeek 2022
Published:
2022-10-20
(Crawled : 19:00)
- biospace.com/
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-77.75%
|
O:
0.39%
H:
2.44%
C:
-4.56%
vaccine
Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants
Published:
2022-10-12
(Crawled : 13:00)
- biospace.com/
JNJ
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-10.02%
|
O:
1.29%
H:
0.0%
C:
0.0%
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-78.97%
|
O:
1.27%
H:
5.93%
C:
5.36%
covid-19
vaccine
prototype
Novavax Announces Initiation of Phase 2b/3 Hummingbird™ Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years
Published:
2022-08-04
(Crawled : 13:20)
- biospace.com/
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-93.47%
|
O:
0.31%
H:
3.16%
C:
1.03%
covid-19
global
children
vaccine
six
trial
phase 2b
Novavax Announces Initiation of COVID-19 Vaccine Booster Study in Adolescents in Phase 3 PREVENT-19 Trial
Published:
2022-04-22
(Crawled : 12:00)
- biospace.com/
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-92.59%
|
O:
-12.19%
H:
4.08%
C:
-1.27%
covid-19
vaccine
trial
phase 3
Initial Results from Novavax' COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine
Published:
2022-04-20
(Crawled : 17:00)
- prnewswire.com
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-92.69%
|
O:
-1.1%
H:
5.48%
C:
-0.56%
covid-19
vaccine
trial
results
Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial
Published:
2022-02-28
(Crawled : 23:00)
- biospace.com/
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-95.11%
|
O:
-0.81%
H:
3.12%
C:
2.96%
covid-19
trial
covid
disease
vaccine
infection
phase 3
infections
Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial
Published:
2022-02-10
(Crawled : 00:00)
- biospace.com/
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-95.65%
|
O:
-4.98%
H:
0.0%
C:
0.0%
covid-19
trial
covid
event-19
positive results
positive
vaccine
phase 3
Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies
Published:
2021-12-22
(Crawled : 23:00)
- biospace.com/
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-97.91%
|
O:
0.11%
H:
1.0%
C:
-4.17%
covid-19
covid
vaccine
Novavax Announces Initiation of PREVENT-19 COVID-19 Vaccine Phase 3 Trial Booster Study
Published:
2021-12-21
(Crawled : 23:00)
- prnewswire.com
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-97.91%
|
O:
0.11%
H:
1.0%
C:
-4.17%
event-19
covid-19
trial
covid
vaccine
phase 3
Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases
Published:
2021-09-24
(Crawled : 01:00)
- prnewswire.com
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-98.45%
|
O:
0.0%
H:
0.0%
C:
0.0%
disease
infectious disease
results
vaccine
influenza
phase 3
trial
lancet
Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza
Published:
2021-09-08
(Crawled : 13:00)
- biospace.com/
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-98.53%
|
O:
0.92%
H:
1.74%
C:
-2.29%
covid
phase 1
vaccine
influenza
trial
phase 2
phase 3
covid-19
Novavax Statement on CDC Guidance Update for COVID-19 Clinical Trial Participants
Published:
2021-08-30
(Crawled : 21:00)
- biospace.com/
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-98.24%
|
O:
-1.04%
H:
6.19%
C:
3.98%
covid
trial
covid-19
Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine
Published:
2021-06-30
(Crawled : 22:00)
- prnewswire.com
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-98.12%
|
O:
1.27%
H:
0.47%
C:
0.35%
covid
results
vaccine
phase 3
trial
Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
Published:
2021-06-14
(Crawled : 10:00)
- prnewswire.com
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-98.1%
|
O:
7.52%
H:
1.8%
C:
-7.86%
covid
disease
vaccine
phase 3
trial
New England Journal of Medicine Publishes Phase 2b Clinical Trial Results Demonstrating Efficacy of Novavax COVID-19 Vaccine Against the B.1.351 Variant
Published:
2021-05-05
(Crawled : 01:00)
- biospace.com/
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-97.79%
|
O:
3.47%
H:
4.31%
C:
-8.13%
covid
phase 2
results
vaccine
phase 2b
trial
trial results
Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine
Published:
2021-05-03
(Crawled : 12:57)
- prnewswire.com
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-98.32%
|
O:
0.66%
H:
0.54%
C:
-18.19%
covid
expansion
vaccine
phase 3
trial
covid-19
Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet
Published:
2021-04-23
(Crawled : 10:00)
- prnewswire.com
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-98.08%
|
O:
0.1%
H:
3.12%
C:
0.05%
phase 2
results
vaccine
phase 2b
trial
trial results
lancet
malaria
Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
Published:
2021-02-26
(Crawled : 14:00)
- biospace.com/
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-21.01%
|
O:
0.72%
H:
0.5%
C:
-0.95%
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-98.2%
|
O:
1.81%
H:
3.52%
C:
2.54%
covid
phase 1
vaccine
license
trial
phase 3
phase 2
← Previous
1
2
Next →
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.